MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1136/rmdopen-2023-003981

Медицинская библиотека · RMD open · 2024

Analysis of belimumab prescription and outcomes in a 10-year monocentric cohort: is there an advantage with early use?

Tani Chiara, Zucchi Dina, Cardelli Chiara, Elefante Elena, Signorini Viola, Schilirò Davide, Cascarano Giancarlo, Gualtieri Luca, Valevich Anastasiya, Puccetti Giulia, Carli Linda, Stagnaro Chiara, Mosca Marta

СтатьяПеревод в очереди

Аннотация

OBJECTIVE

The objective is to evaluate perscriptions of belimumab (BEL), how these have changed over the years and their impact on clinical outcomes in patients with systemic lupus erythematosus (SLE).

METHODS

This is a retrospective analysis of prospectively collected data. We retrieved demographic and clinical data and concomitant therapies at BEL starting (baseline). Disease activity was assessed at baseline and after 6 and 12 months and organ damage at baseline and at the last visit.

RESULTS

From 422 patients followed in the Pisa SLE cohort, 102 patients received BEL and were included and 22 (21.6%) were immunosuppressant (IS)-naïve. Lupus Low Disease Activity State (LLDAS) with a glucocorticoid (GC) dosage ≤5 mg/day (LLDAS5) and remission were achieved by 47% and 38% of patients at 6 months, and by 75% and 66% at 12 months. Comparing IS-naïve patients with those who received BEL after at least one conventional IS, we did not find significant differences in baseline characteristics and in the achievement of LLDAS5 and remission. Despite at baseline we did not observe significant differences in mean GC daily dosage, IS-naïve patients were taking a significantly lower GC daily dose at 6 and 12 months. Interestingly, IS-naïve patients were more common in the most recent years.

CONCLUSIONS

Our data confirm that BEL is effective in controlling disease activity, and in recent years BEL has been considered as an earlier treatment option before other IS. Early introduction of BEL can be at least as effective as a step-up approach and can help to reduce the GC dosage.

Для цитирования: Tani Chiara, Zucchi Dina, Cardelli Chiara, Elefante Elena, Signorini Viola, Schilirò Davide, Cascarano Giancarlo, Gualtieri Luca, Valevich Anastasiya, Puccetti Giulia, Carli Linda, Stagnaro Chiara, Mosca Marta. Analysis of belimumab prescription and outcomes in a 10-year monocentric cohort: is there an advantage with early use?. RMD open. 2024. DOI: 10.1136/rmdopen-2023-003981.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.